Healthcare / Elderly CareUS
← Sticker Wall
JOURNEY · DETAIL
Hims & Hers: From Hair Loss Care E-Commerce to Telehealth Publicly Traded Platform
Founded: Andrew Dudum, Jack Abraham, Hilary Coles, Joe Spector · Hims & Hers Health, Inc.
JOURNEY
Key Fields
FIELD STAMPSIndustryHealthcare / Elderly Care
RegionUS
ScaleGiant
ChannelOther
Origin
In 2017, Andrew Dudum incubated the company via Atomic, targeting awkward health issues men are reluctant to visit doctors for—hair loss and erectile dysfunction—using online consultations and direct-to-door prescription shipping to bypass offline clinical embarrassment. The brand intentionally adopted youth-oriented packaging and humorous marketing, selling prescription drugs like consumer goods. In 2018, it launched the women's line Hers, expanding into skincare, contraception, hair loss, and mental health categories.
Milestones
2017
Founded PMF
In 2017, launched the DTC prescription service for male hair loss and erectile dysfunction under the Hims brand, with first-week orders exceeding expectations, validating the business model of 'stigmatized conditions + online consultation + subscription retention' and securing early investments from Founders Fund and others.
2018
Category Expansion Growth
In 2018, launched the women's brand Hers to enter skincare, contraception, and emotional health. The dual-brand matrix expanded the target demographic to all genders, subscription users continued to climb, and the company valuation entered unicorn status. Both brands shared prescriptions and supply chains, establishing dual subscription cash flows for men and women.
2019
Cost of Expansion Failure
High cash burn for growth led to soaring marketing expenses, resulting in years of consecutive losses. The 2020 prospectus disclosed a cumulative loss of approximately $120 million, raising market skepticism over whether the DTC healthcare unit economic model was viable, a phase lasting from 2019 through 2020. The unit economics were not gradually shifted toward positive cash flow until around 2021.
2021
IPO Turning Point
Went public on the NYSE via a merger with Oaktree Acquisition Corp, backed by Oaktree, at a valuation of approximately $1.6 billion, becoming one of the first publicly traded companies in the telehealth DTC sector, though its stock price subsequently experienced a sharp pullback.
2024
Profitability Inflection PMF
2023 revenue reached $872 million, a year-on-year increase of 65%, with subscription users surpassing 1.5 million and nearing full-year adjusted profitability for the first time, proving that the telehealth subscription model can achieve sound unit economics at scale, a phase spanning from 2022 to 2023.
2024
GLP-1 Boom Growth
Leveraged the weight-loss drug shortage to enter compounded semaglutide injections and oral weight-loss services. In 2024, revenue reached approximately $1.48 billion with over 2.2 million subscription users, and the stock price surged about 250% over the year to become a market star.
2025
Regulatory Storm Inflection
In 2025, the FDA announced the tightening of regulations on compounded drugs following the end of the GLP-1 shortage; Novo Nordisk terminated its partnership and initiated legal disputes, and the FTC filed a lawsuit regarding its business model. The stock price experienced a maximum drawdown of about 78% from its peak, turning unprofitable in Q2 and recording a half-year loss in the magnitude of 1.2 billion RMB.
2025
Settlement & Reshaping Turning Point
Reached a 'century settlement' with Novo Nordisk, gaining authorization to sell legitimate branded weight-loss drugs and raising 2026 revenue guidance to approximately $3.3 billion, while doubling down on an AI-assisted end-to-end custom healthcare platform. The stock price rebounded about 50% from its low, a phase extending from 2025 through 2026.
Turning Points
- The 2021 SPAC listing provided capital ammunition but also exposed the company to strict secondary market scrutiny over losses
- Betting on the GLP-1 weight-loss track in 2024 drove a 250% stock surge while planting hidden risks concerning regulatory and pharmaceutical relationships
- The FDA's tightening of compounded drugs in 2025, combined with Novo Nordisk litigation and FTC investigations, triggered a maximum stock drawdown of 78%
- Securing the right to sell genuine weight-loss drugs following the settlement with Novo Nordisk at the end of 2025 shifted the business model from gray-market compounding to compliant channel distribution
Failures & Pitfalls
- Cumulative pre-IPO losses of approximately $120 million, with DTC-driven growth burning cash long-term without visible profits
- Over-reliance on the gray-market dividend of compounded GLP-1s in 2025, causing the compliance foundation of that business to instantly collapse once the FDA shortage ended
- The breakdown of cooperation with Novo Nordisk escalating into legal disputes, exposing the vulnerability of relying on a single drug supplier and compromise-based negotiations
- Q2 2025 profitability turning negative and half-year losses reaching around 1.2 billion RMB, illustrating that capital expenditures and M&A bets during high-speed growth overextended profits
关键成功要素
- Entering through conditions with 'high social stigma and low offline medical consultation willingness', using branded packaging to lower the user's psychological barrier
- Subscription-based prescription drugs deliver high repeat purchase rates and predictable revenue, with subscription user growth serving as a core valuation metric
- Self-built pharmacies and supply chain integration via M&A to rapidly capture demand during GLP-1 shortages
- Enhancing consultation efficiency and average revenue per user (ARPU) through an AI-personalized platform to hedge against rising customer acquisition cost (CAC) pressures
- Reaching a settlement with Novo Nordisk during a crisis to secure authorized genuine drug licensing, transforming a regulatory crisis into a compliant channel moat
Lessons
- Rapid growth dividends in highly regulated industries often stem from temporary windows; the speed of window closure dictates risk exposure
- Dependence on a single pharmaceutical company or a single drug source leads to a passive position in commercial negotiations
- The DTC subscription model must navigate the dual pressures of customer acquisition costs and compliance costs before achieving profitability
- Periods of stock surges require planning an exit strategy for gray-market operations, treating crisis negotiation capability as a core competency
- The essence of recurring-purchase healthcare is trust capital; brand value and compliance are worth more than growth curves
Core Data
- 2023 Revenue：$872 million (based on public data disclosures, independent review unverified)
- 2024 Revenue：Approx. $1.48 billion (based on public data disclosures, independent review unverified)
- 2026 Revenue Guidance：Approx. $3.3 billion (based on public data disclosures, independent review unverified)
- Subscription Users：2,024 people (based on public data disclosures, independent review unverified)
- Backdoor Listing Valuation：Approx. $1.6 billion (based on public data disclosures, independent review unverified)
- Maximum Stock Drawdown：78% (based on public data disclosures, independent review unverified)
- 2024 Stock Price Increase：Approx. 250% (based on public data disclosures, independent review unverified)
Competitors / Peers
Domestic counterparts include internet healthcare platforms like Ping An Good Doctor and JD Health, though they rely on medical insurance and platform traffic rather than DTC subscriptions. International peers include Ro (telehealth + weight loss), Teladoc, and Amwell. Ro faced similar regulatory dilemmas in GLP-1s, whereas Hims & Hers differentiates itself in repeat purchase rates and ARPU through DTC brand power, a dual-gender/dual-brand matrix, and integrated pharmacies. The focus of group competition is shifting toward AI-personalized healthcare and compliant weight-loss drug channels.